| All patients . | Without 5-ASA . | With 5-ASA . | P-value . | |
|---|---|---|---|---|
| Number of patients | 1284 | 223 | 1061 | |
| Sex: male/female | 752 (58.6%)/532 (41.4%) | 130 (58.3%)/93 (41.7%) | 622 (58.6%)/439 (41.4%) | .94 |
| Age at initiation of UST, median (IQR) | 43.0 (30.0-57.0) | 42.0 (27.0-56.0) | 44.0 (31.0-58.0) | .145 |
| Concomitant 5-ASA | 1061 (82.6%) | 0 (0%) | 1061 (100%) | NA |
| Concomitant IM | 492 (38.3%) | 80 (35.9%) | 412 (38.8%) | .449 |
| Prior PSL use | 930 (72.4%)/354 (27.6%) | |||
| ADT-naïve/ADT exposure | 480 (37.4%)/804 (62.6%) | 68 (30.5%)/155 (69.5%) | 412 (38.8%)/649 (61.2%) | .022 |
| UST intervals: 8 weeks/12 weeks | 1264 (98.4%)/20 (1.6%) | 220 (98.7%)/3 (1.3%) | 1044 (98.4%)/17 (1.6%) | 1.000 |
| All patients . | Without 5-ASA . | With 5-ASA . | P-value . | |
|---|---|---|---|---|
| Number of patients | 1284 | 223 | 1061 | |
| Sex: male/female | 752 (58.6%)/532 (41.4%) | 130 (58.3%)/93 (41.7%) | 622 (58.6%)/439 (41.4%) | .94 |
| Age at initiation of UST, median (IQR) | 43.0 (30.0-57.0) | 42.0 (27.0-56.0) | 44.0 (31.0-58.0) | .145 |
| Concomitant 5-ASA | 1061 (82.6%) | 0 (0%) | 1061 (100%) | NA |
| Concomitant IM | 492 (38.3%) | 80 (35.9%) | 412 (38.8%) | .449 |
| Prior PSL use | 930 (72.4%)/354 (27.6%) | |||
| ADT-naïve/ADT exposure | 480 (37.4%)/804 (62.6%) | 68 (30.5%)/155 (69.5%) | 412 (38.8%)/649 (61.2%) | .022 |
| UST intervals: 8 weeks/12 weeks | 1264 (98.4%)/20 (1.6%) | 220 (98.7%)/3 (1.3%) | 1044 (98.4%)/17 (1.6%) | 1.000 |
Abbreviation: 5-ASA, 5-aminosalicylic acid; ADT, advanced therapy; IMs, immunomodulators; IQR, interquartile range; PSL, predonisolone; UC, ulcerative colitis; UST, ustekinumab.
| All patients . | Without 5-ASA . | With 5-ASA . | P-value . | |
|---|---|---|---|---|
| Number of patients | 1284 | 223 | 1061 | |
| Sex: male/female | 752 (58.6%)/532 (41.4%) | 130 (58.3%)/93 (41.7%) | 622 (58.6%)/439 (41.4%) | .94 |
| Age at initiation of UST, median (IQR) | 43.0 (30.0-57.0) | 42.0 (27.0-56.0) | 44.0 (31.0-58.0) | .145 |
| Concomitant 5-ASA | 1061 (82.6%) | 0 (0%) | 1061 (100%) | NA |
| Concomitant IM | 492 (38.3%) | 80 (35.9%) | 412 (38.8%) | .449 |
| Prior PSL use | 930 (72.4%)/354 (27.6%) | |||
| ADT-naïve/ADT exposure | 480 (37.4%)/804 (62.6%) | 68 (30.5%)/155 (69.5%) | 412 (38.8%)/649 (61.2%) | .022 |
| UST intervals: 8 weeks/12 weeks | 1264 (98.4%)/20 (1.6%) | 220 (98.7%)/3 (1.3%) | 1044 (98.4%)/17 (1.6%) | 1.000 |
| All patients . | Without 5-ASA . | With 5-ASA . | P-value . | |
|---|---|---|---|---|
| Number of patients | 1284 | 223 | 1061 | |
| Sex: male/female | 752 (58.6%)/532 (41.4%) | 130 (58.3%)/93 (41.7%) | 622 (58.6%)/439 (41.4%) | .94 |
| Age at initiation of UST, median (IQR) | 43.0 (30.0-57.0) | 42.0 (27.0-56.0) | 44.0 (31.0-58.0) | .145 |
| Concomitant 5-ASA | 1061 (82.6%) | 0 (0%) | 1061 (100%) | NA |
| Concomitant IM | 492 (38.3%) | 80 (35.9%) | 412 (38.8%) | .449 |
| Prior PSL use | 930 (72.4%)/354 (27.6%) | |||
| ADT-naïve/ADT exposure | 480 (37.4%)/804 (62.6%) | 68 (30.5%)/155 (69.5%) | 412 (38.8%)/649 (61.2%) | .022 |
| UST intervals: 8 weeks/12 weeks | 1264 (98.4%)/20 (1.6%) | 220 (98.7%)/3 (1.3%) | 1044 (98.4%)/17 (1.6%) | 1.000 |
Abbreviation: 5-ASA, 5-aminosalicylic acid; ADT, advanced therapy; IMs, immunomodulators; IQR, interquartile range; PSL, predonisolone; UC, ulcerative colitis; UST, ustekinumab.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
